Bobby Lo

Bobby Lo

Auto-generated profile, based on publicly available information

Bobby Lo

Gastro Unit Medical Section Copenhagen University Hospital—Amager and Hvidovre Hvidovre Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in Nature
Verified
Journal Article
Open access
PDF file
LHLindsay Hracs
Lindsay Hracs
JWJoseph W. Windsor
Joseph W. Windsor
JGJulia Gorospe
Julia Gorospe
MCMichael Cummings
Michael Cummings
SCStephanie Coward
Stephanie Coward
GKGilaad Kaplan
Gilaad Kaplan
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.

1 June 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
BLBobby Lo
Bobby Lo
MZMirabella Zhao
Mirabella Zhao
IVIda Vind
Ida Vind
JBJohan Burisch
Johan Burisch

9 October 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
BLB. Lo
B. Lo
MPM. V. Prosberg
M. V. Prosberg
LGLise Lotte Gluud
Lise Lotte Gluud
WCW. Chan
W. Chan
RLR. W. Leong
R. W. Leong
JBJ. Burisch
J. Burisch

24 August 2020 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
BLBobby Lo
Bobby Lo
IVIda Vind
Ida Vind
MVMarianne Kajbæk Vester-Andersen
Marianne Kajbæk Vester-Andersen
JBJohan Burisch
Johan Burisch
The Danish National Patient Registry (DNPR) has been the source of several epidemiological studies of inflammatory bowel disease (IBD). However, the validation dates back to 1996 and lacks outpatie...

1 August 2019 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
LCLea K Christiansen
Lea K Christiansen
BLBobby Lo
Bobby Lo
FBFlemming Bendtsen
Flemming Bendtsen
IVIda Vind
Ida Vind
MVMarianne K Vester-Andersen
Marianne K Vester-Andersen
JBJohan Burisch
Johan Burisch
Background: Crohn's disease (CD) and ulcerative colitis (UC) are associated with reduced health‐related quality of life (HRQoL), but findings differ between studies. The aim of this study was to analyse the impact of disease activity and social factors on HRQoL.Method: A total of 513 patients diagnosed with UC and CD between 2003 and 2004, in a population‐based setting, were followed for 7 years. HRQoL was assessed using the Short Form‐12, the Short Inflammatory Bowel Disease (IBD) Questionnaire (SIBDQ), the Work Productivity and Activity Impairment Questionnaire: General Health and a national health survey. Associations were assessed using multiple linear regressions.Results: A total of 185 of the eligible patients (UC: 107 (50.2%) and CD: 78 (50.3%)) were included. No differences in disease‐specific or generic HRQoL were found between CD and UC patients, and IBD patients did not differ compared with the background population. The majority of CD (73.1%) and UC (85.0%) patients had ‘good’ disease‐specific HRQoL using the SIBDQ. Unemployment for ≥ 3 months occurred more in CD vs UC patients(30.6 vs 15.5%, p = 0.03); however, sick leave for ≥ 3 months did not differ significantly (17.4 vs 11.4%, p = 0.4). Using multiple linear regressions, unemployment, sick leave and disease activity were the factors most frequently associated with reduced HRQoL.Conclusion: In a population‐based cohort with 7 years of follow‐up, HRQoL did not differ between patients and the background population.

15 July 2022 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
BLBobby Lo
Bobby Lo
ZLZhuoYuan Liu
ZhuoYuan Liu
FBFlemming Bendtsen
Flemming Bendtsen
CIChristian Igel
Christian Igel
IVIda Vind
Ida Vind
JBJohan Burisch
Johan Burisch
Introduction: The evaluation of endoscopic disease severity is a crucial component in managing patients with ulcerative colitis (UC). However, endoscopic assessment suffers from substantial intraobserver and interobserver variations, limiting the reliability of individual assessments. Therefore, we aimed to develop a deep learning model capable of distinguishing active from healed mucosa and differentiating between different endoscopic disease severity degrees. Methods: One thousand four hundred eighty-four unique endoscopic images from 467 patients were extracted for classification. Two experts classified all images independently of one another according to the Mayo endoscopic subscore (MES). In cases of disagreement, a third expert classified the images. Different convolutional neural networks were considered for automatically classifying UC severity. Five-fold cross-validation was used to develop and select the final model. Afterward, unseen test data sets were used for model evaluation. Results: In the most challenging task—distinguishing between all categories of MES—our final model achieved a test accuracy of 0.84. When evaluating this model on the binary tasks of distinguishing MES 0 vs 1–3 and 0–1 vs 2–3, it achieved accuracies of 0.94 and 0.93 and areas under the receiver operating characteristic curves of 0.997 and 0.998, respectively. Discussion: We have developed a highly accurate, new, automated way of evaluating endoscopic images from patients with UC. We have demonstrated how our deep learning model is capable of distinguishing between all 4 MES levels of activity. This new automated approach may optimize and standardize the evaluation of disease severity measured by the MES across centers no matter the level of medical expertise.